FDA-approved Next Generation Sequencing Tests for Tumors of Diverse Histology

7/30/2018

FDA-approved Next Generation Sequencing Tests for Tumors of Diverse Histology

A draft coverage guidance has been posted for comment after review by the Health Technology Assessment Subcommittee (HTAS). The comment periods end at 8 a.m. on 8/13/2018 and comments will be reviewed at the next HTAS meeting.

  • FDA-approved Next Generation Sequencing Tests for Tumors of Diverse Histology 

To review commenting guidelines, and view the drafts, visit our open for comment page.

Questions? Email HERC.Info@state.or.us

Powered By GrowthZone